wwwext.amgen.comOCT 11 min read$AMGN

Amgen Announces Additional Investment In BeiGene| Amgen

Amgen invested $421M in BeiGene's share offering, maintaining a 20.3% stake. The investment supports their oncology collaboration in China, reflecting confidence in the partnership's progress.

Original reporting

wwwext.amgen.com

Published Oct 1, 2026, 12:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 1, 2026, 12:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Amgen Announces Additional Investment In BeiGene| Amgen — source image — Source · wwwext.amgen.com

Decision brief

The 30-second read

$AMGNBearishMed

Why it matters

The deal may influence both companies' stock trajectories and sector sentiment.

Market read

A sizable, first‑time disclosed investment that could affect biotech valuations and US‑China partnership outlook.

What to watch

Potential regulatory or political risks affecting cross‑border biotech deals.

Relevance 1/10Novelty 8/10Timing: today

Background

Amgen's press release details a strategic capital increase in its partner BeiGene.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNBearishHigh confidence

Context

Amgen announced a $421 million additional investment in BeiGene, maintaining a 20.3% stake.

Expected impact

likely modest pressure as market prices in the sizable capital outlay.

Evidence & confidence

The investment is a fresh, material capital deployment disclosed for the first time.

Market effects

Sector

Strengthens the biotech/oncology sector narrative with a high‑profile partnership.

Regional

Highlights continued US‑China biotech collaboration despite geopolitical tensions.

Global

Signals confidence in Chinese oncology market growth to global investors.

Counterpoint

What could challenge this read

The investment could be seen as a risky allocation if BeiGene's trials falter.

Key entities

company
Amgen
US biotech giant making the investment.
company
BeiGene
Chinese biotech receiving the investment.

Read at source ← All news

OCT 1

$AMGNMedAI 9/10

Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

koreabiomed.com2 min

SEP 30

$AMGNMedAI 8/10

Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

simplywall.st3 min

SEP 30

$AMGNMedAI 9/10

Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

fiercebiotech.com2 min

SEP 29

$AMGNHighAI 9/10

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

insidermonkey.com2 min

SEP 29

$AMGNLowAI 9/10

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, boosting its autoimmune pipeline. Shares rose 15.5% in 90 days and 27.6% year-to-date. Analysts debate valuation, with some arguing it's 16.2% overvalued at $418.13, while others see potential in future cash flows. Legacy drug erosion and competitive pressures are key risks.

finance.yahoo.com3 min

SEP 27